ArticleJournal of asthma and allergy2026
Risk Factors for Progression to Chronicity or Recurrent Episodes in Pediatric Acute Urticaria: A 1-Year Cohort Study.
Article in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute urticaria (AU) is common and often considered self-limiting in children; however, a subset may progress to chronic spontaneous urticaria (CSU) or develop recurrent AU. Clinical characteristics associated with these unfavorable outcomes remain poorly characterized. Methods: In this single-center retrospective cohort study, 475 children (<18 years) with AU presenting to dermatology settings were included. Demographic, clinical, and laboratory data were extracted from electronic medical records. Personal and family histories of atopy were confirmed, and 1-year outcomes were assessed via structured telephone follow-up. Independent risk factors were identified using Firth penalized multivariable logistic regression. Results: Follow-up was completed for 358 of 475 (75.4%) patients. Median age was 4.25 years, with 51% being male. At 1 year, 50 patients (14.0%) progressed to CSU and 37 patients (10.3%) experienced recurrent AU. Firth penalized multivariable analysis identified non-first-episode presentation (CSU: aOR 7.89, 95% CI 3.54-17.92; recurrent AU: aOR 6.73, 95% CI 2.57-17.31) and family history of CSU (CSU: aOR 4.35, 95% CI 1.27-13.65; recurrent AU: aOR 8.85, 95% CI 2.76-27.19) as independent predictors of both adverse outcomes. Family history of asthma was associated with CSU progression (aOR 32.26, 95% CI 1.67-477.76), and family history of chronic inducible urticaria was associated with recurrent AU (aOR 9.07, 95% CI 2.02-40.99); however, these estimates were imprecise because of small exposed case numbers. Notably, systemic corticosteroid use was not independently associated with either adverse outcome. Conclusion: Recurrent AU, in addition to CSU progression, is an important 1-year outcome after pediatric AU. Non-first-episode AU and family history of CSU are readily ascertainable predictors that enable early risk stratification and follow-up. The single-center retrospective design and loss to follow-up should be considered when interpreting the generalizability of these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.